Novocardia™ Recognized as a Rising Disruptor by Bernstein in U.S. Health Care Services

Novocardia Joins List of Fast-Growing Private Companies Transforming Health Care Delivery & Outcomes

    NEW YORK, Nov. 18, 2021 /PRNewswire/— Novocardia, a value-based cardiovascular disease care delivery platform, today announced it has been named a “Rising Disruptor” by Bernstein, a global equity research firm, in its 2021 report on the most disruptive private health care services companies in the United States.

    The “2021 Bernstein Disruptors 25” report recognizes private health care companies that are innovative leaders positioned to transform the efficiency, outcomes, or delivery of care in the United States. Bernstein analysts selected companies leading major disruption trends, including value-based care, digital-first health care, reinventing care delivery, and whole person health/health equity.

    The report ranked this year’s top 25 Disruptors and named Rising Disruptors, which are earlier-stage companies that represent important disruption themes and have the potential for significant impact on how health care is delivered. Novocardia was selected as one of six Rising Disruptors.

    “Novocardia is thrilled to be recognized by Bernstein as a Rising Disruptor in U.S. health care services,” said Daniel Blumenthal, MD, MBA, Chief Executive Officer of Novocardia.

    “We are truly passionate about improving the delivery of cardiovascular care in this country, and we believe empowering cardiologists through value-based care, and fee-for-value reimbursement models is the vehicle through which we make that happen. Novocardia is proud to be at the forefront of this pivotal transformation in cardiovascular care.”

    Bernstein analysts identified the shift to value-based care as the largest disruption to the U.S. health care system. According to the report, value-based care has the potential to reduce health care costs by $1 trillion. The current value-based care sector is estimated to grow from $250 billion today to nearly $900 billion in 2030 and increase total medical spending from 2% in 2020 to 12% by 2030.*

    “Novocardia’s significant potential to change cardiovascular disease care through a value-based care delivery platform emphasizing proactive and prevention-focused care made the company stand out as a Rising Disruptor,” said Lance Wilkes, Bernstein’s Senior Analyst covering U.S. Health Care Services. “With increasing demands for cost-effectiveness, convenience, and improved health outcomes, the pace of disruption in the health care industry is continuing to accelerate, and we look forward to seeing how Novocardia grows in the new year.”

    * Bernstein, September 2021, “The 2021 Bernstein Disruptors 25,”


    Founded in 2020, Novocardia is on a mission to transform how cardiovascular disease care is delivered in the United States and help patients with heart and vascular disease live longer, healthier, and more satisfying lives. Novocardia is committed to putting cardiologists, and their patients, at the center of care by investing in our partner practices, deploying purpose-built data and analytics tools to improve patient outcomes, and enabling our partners to transition more successfully to value-based care. To learn more about Novocardia, please visit


    Founded more than 50 years ago, Bernstein Private Wealth Management, a unit of AllianceBernstein L.P. (A.B.), provides investment planning advice and services to individuals, families, endowments, foundations, and other financial guardians, so that they can reach their long-term investment objectives. Our global research enables us to customize a portfolio that suits any investment goal, income need, tax situation, or tolerance for risk. The firm managed $110 billion in assets as of March 31, 2021. For more information, visit

    Media Contacts:

    Kathryn Hughes
    Acting Chief Marketing Officer

    Lou Hughes
    Moving Minds


    Novocardia™ Named Among
    New York City's Top 101 Health Care
    Companies and Startups of 2021

    Company Recognized for Leading Innovation in Cardiovascular Disease Care with Value-Based Care Delivery Platform

    Novocardia™ Enters Into
    Partnership with MedAxiom™

    Strategic Alliance Focused on Promoting Common Mission of Transforming Quality, Value, and Outcomes of Cardiovascular Care

    Novocardia™ Announces
    Key Additions to Leadership Team
    Accelerating Company’s Mission
    & Growth

    Executives Bring Decades of Multifaceted Health Care Experience that Will Enable Cardiologists to More Successfully Navigate Shifts in Cardiovascular Disease Care

    Novocardia™ Announces
    Partnership with First Coast Heart
    & Vascular Center

    Alliance to Focus on Improving the Quality, Access, and Value
    of Cardiovascular Disease Care in Northeast Florida

    Novocardia™ Announces
    $53.7 Million Financing Led
    by Deerfield Management

    New Venture to Partner with Cardiologists to Improve the Quality
    and Value of Cardiovascular Care in the United States
    Contact Us
    345 Park Avenue South, 12th Floor
    New York, NY 10010
    Get Novocardia news, events, and innovations delivered right to your inbox.